Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXN | P10599 | 2/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | AR | P10275 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651407 | 0.87 | TXN (0.77) | TXNBCHERAB9ANPC1POLB | |
| SCHEMBL28782649 | 0.87 | TXN (0.77) | TXNBCHERAB9ANPC1POLB | |
| SCHEMBL11823551 | 0.86 | TXN (0.75) | TXNBCHERAB9ANPC1POLB | |
| SCHEMBL159798 | 0.83 | TXN (0.72) | TXNBCHERAB9ANPC1POLB | |
| SCHEMBL7998438 | 0.82 | BCHE (0.73) | TXNBCHERAB9ANPC1POLB | |
| SCHEMBL31175737 | 0.82 | BCHE (0.73) | TXNBCHERAB9ANPC1POLB | |
| SCHEMBL1605263 | 0.82 | TXN (0.68) | TXNBCHERAB9ANPC1POLB | |
| SCHEMBL1604294 | 0.82 | TXN (0.68) | TXNBCHERAB9ANPC1POLB | |
| SCHEMBL1119596 | 0.82 | TXN (0.68) | TXNBCHERAB9ANPC1POLB | |
| SCHEMBL3688773 | 0.81 | TXN (0.70) | TXNBCHERAB9ANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398682-B2 | Methods and compositions to prevent or treat bacterial infections | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-03 | — | — | US | claimed |
| WO-2015009699-A1 | METHODS AND COMPOSITIONS TO PREVENT OR TREAT BACTERIAL INFECTIONS | KETTER PATRICK (US) | 2015-01-22 | — | — | WO | claimed |
| JP-56120737-A | — | — | None | — | — | JP | disclosed |
| US-11129811-B2 | Methods and compositions to prevent or treat bacterial infections | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-28 | — | — | US | disclosed |
| US-10478485-B2 | Methods and compositions to prevent or treat bacterial infections | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-11-19 | — | — | US | disclosed |
| US-10398682-B2 | Methods and compositions to prevent or treat bacterial infections | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180193442-A1 | METHODS AND COMPOSITIONS TO PREVENT OR TREAT BACTERIAL INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-07-12 | — | — | US | disclosed |
| US-20170266198-A1 | MODULATION OF TISSUE TRANSGLUTAMINASE ACTIVATION IN DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-09-21 | — | — | US | disclosed |
| US-20170266198-A1 | MODULATION OF TISSUE TRANSGLUTAMINASE ACTIVATION IN DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-09-21 | — | — | US | disclosed |
| WO-2017004545-A1 | METHODS AND COMPOSITIONS TO PREVENT OR TREAT BACTERIAL INFECTIONS | KETTER PATRICK (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20160151333-A1 | METHODS AND COMPOSITIONS TO PREVENT OR TREAT BACTERIAL INFECTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-06-02 | — | — | US | disclosed |
| WO-2015009699-A1 | METHODS AND COMPOSITIONS TO PREVENT OR TREAT BACTERIAL INFECTIONS | KETTER PATRICK (US) | 2015-01-22 | — | — | WO | disclosed |
| US-20140322278-A1 | Modulation of Tissue Transglutaminase Activation in Disease | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322278-A1 | Modulation of Tissue Transglutaminase Activation in Disease | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-10-30 | — | — | US | disclosed |
| WO-2012177640-A2 | MODULATION OF TISSUE TRANSGLUTAMINASE ACTIVATION IN DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-12-27 | — | — | WO | disclosed |
| JP-S56120737-A | PREVENTION OF SCORCHING OF HALOGEN-CONTAINING POLYMER RUBBER | SANSHIN KAGAKU KOGYO KK | 1981-09-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322278-A1 | Modulation of Tissue Transglutaminase Activation in Disease | SI, TGM2, DSG1 | TXN 1498/4885BCHE 1014/4885RAB9A 1481/4885 |
| US-20170266198-A1 | MODULATION OF TISSUE TRANSGLUTAMINASE ACTIVATION IN DISEASE | SI, TGM2, DSG1 | TXN 1498/4885BCHE 1014/4885RAB9A 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.